Host B cells produce IL-10 following TBI and attenuate acute GVHD after allogeneic bone marrow transplantation

Royal Brisbane Hospital, Brisbane, Queensland, Australia
Blood (Impact Factor: 9.78). 11/2006; 108(7):2485-92. DOI: 10.1182/blood-2006-04-016063
Source: PubMed

ABSTRACT Host antigen-presenting cells (APCs) are known to be critical for the induction of graft-versus-host disease (GVHD) after allogeneic bone marrow transplantation (BMT), but the relative contribution of specific APC subsets remains unclear. We have studied the role of host B cells in GVHD by using B-cell-deficient microMT mice as BMT recipients in a model of CD4-dependent GVHD to major histocompatibility complex antigens. We demonstrate that acute GVHD is initially augmented in microMT recipients relative to wild-type recipients (mortality: 85% vs 44%, P < .01), and this is the result of an increase in donor T-cell proliferation, expansion, and inflammatory cytokine production early after BMT. Recipient B cells were depleted 28-fold at the time of BMT by total body irradiation (TBI) administered 24 hours earlier, and we demonstrate that TBI rapidly induces sustained interleukin-10 (IL-10) generation from B cells but not dendritic cells (DCs) or other cellular populations within the spleen. Finally, recipient mice in which B cells are unable to produce IL-10 due to homologous gene deletion develop more severe acute GVHD than recipient mice in which B cells are wild type. Thus, the induction of IL-10 in host B cells during conditioning attenuates experimental acute GVHD.

  • [Show abstract] [Hide abstract]
    ABSTRACT: The last six decades have seen major advances in the understanding of immunological diseases, driven by preclinical animal models. Indeed, bone marrow transplantation (BMT) has its genesis in rodent models dating back to the 1950's. Allogeneic BMT and its major complication, graft-versus-host disease (GVHD), represent a paradigm for the translational of preclinical concepts into clinical practice. The appreciation that GVHD can be thought of as a step-wise, escalation in immune activation characterized by eventual massive target tissue apoptosis has allowed the design of rational approaches to better manage patients. Here we describe the pathophysiology of GVHD as defined in preclinical models, focusing on the successes and failures of this research to instruct and translate clinical practice. We also provide a commentary on the limitations of these models so that they may be better appreciated and addressed in future studies. Notable preclinical successes include the definition of modern immune suppression, reductions in conditioning intensity, post-transplant cyclophosphamide and the promotion of regulatory T cell reconstitution. New strategies including naïve T cell depletion, focused cytokine and chemokine inhibition and the blockade of costimulation now also appear highly promising and very likely to translate into patients in the near future.
    Blood 06/2014; 124(3). DOI:10.1182/blood-2014-02-514745 · 9.78 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Most ligands from the tumour necrosis factor (TNF) superfamily play very important roles in the immune system, and particularly so in B lymphocyte biology. TNF ligands are essential to many aspects of normal B cell biology from development in the bone marrow to maturation in the periphery as well as for activation and differentiation into germinal centre, memory or plasma cells. TNF ligands also influence other aspects of B cell biology such as their ability to present antigens or regulate immune responses. Importantly, inadequate regulation of many TNF ligands is associated with B cell disorders including autoimmunity and cancers. As a result, inhibitors of a number of TNF ligands have been tested in the clinic, with some becoming very successful approved treatments alleviating B cell-mediated pathologies.
    Seminars in Immunology 07/2014; DOI:10.1016/j.smim.2014.06.001 · 6.12 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Reproductive immunology research has long focused on T cell responses to paternal antigens and tolerance mechanisms supporting fetal well-being. The participation of B cells herein was not widely studied. Because of the fascinating immunological uniqueness of pregnancy it is however to be expected that such pleiotropic cells play a considerable role. In fact, on the one hand B cells contribute towards pregnancy tolerance by secreting the immunomodulatory cytokine IL-10 but on the other hand can seriously harm pregnancy because of their capacity of producing autoantibodies. As for protective B cells, new evidences in mouse models arise suggesting that IL-10 producing B cells, the so called B10 cells, help in maintaining tolerance towards semiallogenic fetal antigens. They may be also important to fight danger signals at the fetal- maternal as e.g. in the case of infections with the aim to restore the disrupted fetal tolerance. In human pregnancies, IL-10 producing B cells increase with pregnancy onset but not in the case of spontaneous abortions. In vitro, they are able to suppress TNF-α production by T cells from pregnant individuals. Their generation and functionality will be discussed throughout this review article. B cells can be deleterious to pregnancy as well. Aberrant B cell compartment is associated with obstetric pathologies. In particular the capacity of B2 cells to produce specific autoantibodies or of B1aB cells to secrete natural autoantibodies that can turn autoreactive will be discussed herein.
    Frontiers in Immunology 06/2014; 5:285. DOI:10.3389/fimmu.2014.00285

Full-text (3 Sources)

Available from
May 21, 2014